-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AD-214 in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AD-214 in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AD-214 in Chronic Kidney Disease (Chronic Renal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AD-214 in Kidney Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AD-214 in Kidney Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AD-214 in Kidney Fibrosis Drug Details: AD-214 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AD-214 in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AD-214 in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AD-214 in Idiopathic Pulmonary Fibrosis Drug Details: AD-214 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SSGJ-611 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SSGJ-611 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SSGJ-611 in Atopic Dermatitis (Atopic Eczema) Drug Details: Monoclonal antibody...
-
Product Insights
Hypertrophic Scars – Drugs In Development, 2023
Global Markets Direct’s, ‘Hypertrophic Scars - Drugs In Development, 2023’, provides an overview of the Hypertrophic Scars pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypertrophic Scars, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Kidney Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Kidney Fibrosis - Drugs In Development, 2023’, provides an overview of the Kidney Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Kidney Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) - Drugs In Development, 2023’, provides an overview of the Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2023
Empower your strategies with our Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2024 report and make more profitable business decisions. Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups, and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity, and high cholesterol. The Chronic Kidney Disease (Chronic Renal...
-
Product Insights
Osteoporosis – Drugs In Development, 2023
Empower your strategies with our Osteoporosis – Drugs In Development, 2024 report and make more profitable business decisions. Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, and a bone fracture that occurs much more easily than...
-
Product Insights
Interstitial Lung Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Interstitial Lung Fibrosis - Drugs In Development, 2023’, provides an overview of the Interstitial Lung Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Lung Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...